Möchten Sie immer auf dem neuesten Stand bleiben?

Oslo, Norway, December 27, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces an update on Cevira, which is...

Oslo, Norway, 19 December 2014 Photocure ASA presents its financial calendar for 2014: 27 February 2014 - Presentation of the fourth quarter and full year 2013 7 May 2014 - Presentation of the...

Oslo, Norway, November 28, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces that the US Centers for...

  This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. ...

  This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. ...

Oslo, Norway, November 6, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announced today that data will be...

Novel treatment for moderate to severe acne Oslo, Norway, October 30, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and...

Oslo, Norway, 23 October 2013: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the third...

Photocure will present its third quarter 2013 report on Wednesday 23 October 2013 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company...

The annual report for Photocure ASA (the "Company") for 2012 has previously been made available at the Company's web page: http://www.photocure.com/Investor-relations/, and is now also published on...